linjc16/ctgov huggingface dataset:
Effect of Electrical Stimulation at Acupoints on Blood Pressure

Study Overview
=================
Brief Summary
-----------------
To determine if electrical stimulation on acupoints has any effect on hypertensive subjects.

Detailed Description
-----------------
All subjects will be assigned into control and experimental groups by a random table. The first 40 numbers in the first row will be used for the study. Subjects assigned with an odd number will be divided into the control group. ROLE OF SUBJECTS Subjects in the experimental will receive Hans treatment for hypertension. No invasive procedures will be used for subjects in either the control and experimental groups. This randomized controlled study will recruit hypertensive subjects into control and experimental groups using a random table. Only the subjects in the experimental group use Hans stimulation as a treatment for high blood pressure. The treatment regiment is discussed in the Treatment section in detail. The subjects in the control group will not

Official Title
-----------------
Pilot Study Using Electrical Stimulation on Hypertension

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Device: Hans unit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of mild hypertension (160-140/100-90 mmHg), male and female subjects with any racial background will be invited to participate in the study. All adult age groups are included in the study. Subjects must sign an informed consent form. Exclusion Criteria: Diagnosis of severe hypertension (200-161/120-101 mmHg), limited physical activity, heart failure, kidney diseases and mental diseases are excluded in the study. A questionnaire will be used in the initial patient screening.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Hans unit|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure measurements. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypertension, Hans, Electrical stimulation
A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to track changes in overactive bladder (OAB) medical regimen and/or OAB medication dosage requirements.

Detailed Description
-----------------
Subjects will complete a study specific survey questionnaire at Screening and the Month 1 through Month 6 visits. Subjects will be followed for 6 months.

Official Title
-----------------
A Phase 4, Observational, Non-interventional Study Measuring and Tracking Changes in Overactive Bladder Medication and/or Overactive Bladder Medication Dose in Subjects With Overactive Bladder

Conditions
-----------------
Overactive Bladder (OAB)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject has overactive bladder as determined by their prescribing physician Subject is currently receiving pharmacotherapy for overactive bladder Subject is willing to comply with required protocol/study requirements Exclusion Criteria: Subject has a history of a clinically significant illness or medical condition prior to screening that would preclude participation in the study Male subjects with Lower Urinary Tract Symptoms (LUTS) or Bladder Outlet Obstruction (BOO)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Subjects with Overactive Bladder (OAB)<br>Combination of new OAB subjects and existing subjects on OAB medication | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in overactive bladder (OAB) medication/ treatment regimen |  | 6 months | 
| Reason for change in OAB medication/treatment regimen |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Persistence of use of any OAB medication as reported by the Physician |  | 6 months | 
| Change in OAB medication including discontinuation of OAB medication as reported by the Physician |  | 6 months | 
| Subject reported efficacy | Measured by the Subject Survey Questionnaire | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Overactive Bladder (OAB), Observational, Registry
Comparison of Bupivacaine and Exparel for Carpal Tunnel Release

Study Overview
=================
Brief Summary
-----------------
Carpal tunnel syndrome is one of the most common surgeries performed per year in the United States, accounting for over 600,000 surgeries. The procedure is commonly performed under light sedation and local anesthesia. Bupivicaine, a long acting local anesthetic, has been used to allow extended pain relief for 8-10 hours after carpal tunnel release. Exparel, a liposomal bupivicaine formulation, has been documented to provide pain relief for up to 72 hours post-operatively. By decreasing post-operative pain through the use of a long-acting local anesthetic, the use of narcotic pain medications may be decreased and patient satisfaction scores may increase. The purpose of this study is to prospectively compare bupivicaine and liposomal bupivicaine with respect to post-operative pain control, narcotic usage, and patient satisfaction after carpal tunnel release.

Official Title
-----------------
Does Long-Acting Liposomal Bupivacaine Provide Improved Pain Relief Over Bupivicaine Alone in Carpal Tunnel Release?

Conditions
-----------------
Pain After Carpal Tunnel Release

Intervention / Treatment
-----------------
* Drug: Bupivacaine
* Drug: Exparel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with carpal tunnel syndrome undergoing surgery Exclusion Criteria: Non english speaking Allergy to bupivacaine or exparel

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Bupivacaine<br>Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery | Drug: Bupivacaine<br> <br> |
| Experimental: Exparel<br>Patients will received Exparel subcutaneously for local anesthesia during surgery | Drug: Exparel<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain | Pain will be evaluated using an 11-point ordinal scale (0-10) | Starting immediately after surgery and then every 8 hours for 10 days |
Feasibility and Outcomes of Repetitive Radial Approach

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the feasibility of performing repetitive coronary angiograms via the radial approach

Detailed Description
-----------------
Assessing succes of radial access in patients with prior TRA procedures

Official Title
-----------------
Feasibility and Outcomes of Repetitive Radial Approach

Conditions
-----------------
Injury of Radial Artery

Intervention / Treatment
-----------------
* Other: Cath


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with previous successful radial artery approach scheduled for elective transradial coronary angiography Exclusion Criteria: Lack of indication to perform radial approach Abnormal Barbeau test result (type C and D) Presence of radial artery occlusion Previous important trauma of the upper limbs Presence of fistula for renal dialysis Lymphoedema Acute myocardial infarction Refusal to sign the informed consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cath patients<br>Patients with previous cardiac cath via the radial access who are planned for additional radial access cardiac cath | Other: Cath<br>* No intervention - registry<br>* Other names: No intervention - registry;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess patency of radial artery after repetitive radial artery access |  | 1 month |
A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders

Study Overview
=================
Brief Summary
-----------------
To investigate the safety of partially matched related human placental-derived stem cells (HPDSC) administered in conjunction with umbilical cord blood (UCB) stem cells from the same donor in subjects with various malignant or nonmalignant disorders potentially curable with stem cell transplantation and to assess potential restoration of normal hematopoiesis and immune function in subjects with these disorders

Official Title
-----------------
A Single-Arm Study to Assess the Safety of Transplantation With Umbilical Cord Blood Augmented With Human Placental-Derived Stem Cells From Partially Matched Related Donors in Subjects With Certain Malignant Hematologic Diseases and Non-Malignant Disorders

Conditions
-----------------
Hematologic Malignancies

Intervention / Treatment
-----------------
* Procedure: UCB and HPDSC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: suitable UCB collected from partially or fully HLA matched related donor subject requires umbilical cord transplantation Exclusion Criteria: any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study major anticipated illness or organ failure incompatible with survival from stem cell transplant

Ages Eligible for Study
-----------------
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>all subjects will be treated with UCB and HPDSC | Procedure: UCB and HPDSC<br>* single dose of UCB followed by one unit of HPDSC<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of GVHD, time to engraftment and survival |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Myelodysplastic Syndrome (MDS), Acute myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Sickle Cell Disease (SCD), Beta Thalassemia, Inborn Errors of Metabolism, Severe Combined Immunodeficiency Disease (SCID)
Determination of Specific Biomarkers of Angioneurotic Crisis

Study Overview
=================
Brief Summary
-----------------
Diagnosis of angioedema (AE) is difficult especially in emergency room. Two forms should be evoked: histaminic AE (allergic or not, which represent 95% of cases) and bradykinic AE (hereditary or acquired deficiency, with or without C1 Inhibitor) rarer but with more severe prognosis. The distinction is based on clinical features (spontaneous crisis duration, presence of concomitant hives, atopic history...). Sometimes it could be difficult to make the difference. Nowadays, there is no biological marker of the crisis. The search for biomarkers could improve the diagnostic and therapeutic management of AE. Previous work has identified targets: D-dimer, C4, and VE-cadherin. We wanted to know the sensitivity and specificity of these markers. We conducted a prospective study evaluating the D-dimer assays, complement and VE-cadherin during an episode of AE. Three groups of patients were tested: bradykinic AE (peripheral or abdominal attacks), histaminic AE, and abdominal pain (non-bradykinic and non-histaminic etiology) at the time (day 0) and at distance from the crisis (D7).

Official Title
-----------------
Determination of Specific Biomarkers of Angioneurotic Crisis

Conditions
-----------------
Angioedema

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histaminergic or bradykinin angioedema Abdominal pain Exclusion Criteria: children < 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| bradykinin angioedema<br>Hereditary angioedema with or without C1Inhibitor Drug induced angiodema | |
| Histaminergic angioedema<br>Allergic and non allergic angioedema | |
| Control group<br>Patients with abdominal pain | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VE CADHERIN SENSITIVITY AND SPECIFICITY |  | 7 DAYS | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| D-DIMERS SENSITIVITY AND SPECIFICITY |  | 7 DAYS | 
| C1INHIBITOR |  | 7 DAYS | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
angioedema, C1Inhibitor, bradykinin, Histamin
Bronchial Alpha Amylase as a Marker for Early Aspiration Pneumonia in Therapeutic Hypothermia.

Study Overview
=================
Brief Summary
-----------------
Early Aspiration Pneumonia is a frequent and dreadful complication in survivors of cardiac arrest. Therapeutic Hypothermia widely used in Intensive Care Unit for its benefice on post cardiac arrest syndrome may otherwise hide signs of early pneumonia that may occur without use of a reliable screening biological marker. The goal is to assess the diagnostic accuracy of bronchial alpha amylase measure to predict a risk of early aspiration pneumonia in patients successfully resuscitated after out-of-hospital cardiac arrest. In this prospective non interventional study we included patients resuscitated after cardiac arrest and treated with Targeted Temperature Management (TTM). A distal bronchoalveolar lavage using specific display (Combi-Cath) was executed immediately after admission for each patient with both biochemic and bacteriological analysis including dosage of bronchial salivary alpha amylase. Urea was used as a marker of dilution in the measure of bronchial and plasmatic alpha amylase. Aspiration pneumonia diagnosis was established with clinical and biological criteria. On this basis we intended to determine a threshold measure of alpha amylase predicting occurrence of aspiration pneumonia and allowing a guidance in antibiotherapy prescription. Sensibility and Specificity of this technique were determined.

Official Title
-----------------
Salivary Alpha Amylase Bronchial Measure for Early Aspiration Pneumonia Diagnosis in Patients Treated With Therapeutic Hypothermia After Out-of-hospital Cardiac Arrest.

Conditions
-----------------
Early Aspiration Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Well resuscitated patients after out-of-hospital cardiac arrest Indication of Therapeutic Temperature Management Patients aged over 18 years Immediate or deferred acceptation of study Exclusion Criteria: Patients aged under 18 years. Pregnant women. Against indication to therapeutic hypothermia. Active therapeutic limitation after admission. Patient without social security.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early Aspiration Pneumonia | Diagnosis of aspiration pneumonia after cardiac arrest with clinical, biological and radiological criteria including fever, leucocytes, broncho alveolar secretion, chest radiography and bacteriological identification. | Within 5 days |
The Different Running Speeds of Strike Patterns

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to investigate the differences of landing patterns while running in different speed with barefoot and wearing shoe.

Detailed Description
-----------------
Running speed will be adjusted with physical strength and circumstance. When speed changes, whether the landing patterns change or not may be one factor of sports injuries. Therefore, the purpose of this research is to investigate the differences of landing patterns while running in different speed with barefoot and wearing shoe.

Official Title
-----------------
Analysis of the Different Running Speeds of Strike Patterns: The Efficiency of Shoes

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Other: Barefoot
* Other: In shoes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To jog at least three times a week, each time lasted for more than 20 minutes No smokers No musculoskeletal diseases within 6 months Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: barefoot first<br>Ten runners carried on barefoot test first and then in-shoes. | Other: Barefoot<br>* barefoot running test was 20 minutes.<br>Other: In shoes<br>* In shoes test was 20 minutes.<br>|
| Other: in shoes first<br>Ten runners carried on in-shoes test first and then barefoot. | Other: Barefoot<br>* barefoot running test was 20 minutes.<br>Other: In shoes<br>* In shoes test was 20 minutes.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The percentage of three kinds of landing patterns. |  | 20 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
running speeds, strike patterns
Medicaid Disenrollment: Intrastate Emergency Department Impact

Study Overview
=================
Brief Summary
-----------------
We will obtain data from the robust Agency for Healthcare Reimbursement and Quality (AHRQ) Healthcare Utilization Project (HCUP), as well as from the State of Tennessee. If our hypotheses are true, such data will provide strong evidence that Medicaid disenrollment has a negetive health impact on uninsured populations. The data may also provide evidence for increased public funding of safety-net EDs after Medicaid disenrollment.

Official Title
-----------------
Medicaid Disenrollment: Intrastate Emergency Department Impact

Conditions
-----------------
Medicaid Enrollment Status

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: data will be obtained from the Agency for Healthcare Reimbursement and Quality (AHRQ) Healthcare Utilization Project (HCUP) Exclusion Criteria: n/a
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of ED visits from uninsured and TennCare patients after TennCare disenrollment | The proportion of ED visits from uninsured and TennCare patients after TennCare disenrollment | Upon record review | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Medicaid, Disenrollment
Progression to Impaired Glucose Tolerance and Type 2 Diabetes in the Korean People-based KNDP Study

Study Overview
=================
Brief Summary
-----------------
Impaired glucose tolerance is a metabolic state between normal glucose homeostasis and diabetes. Previously, prospective studies have shown higher progression rates from IGT to diabetes in other country. But There is no prospective-multicenter based reports in Korea. Therefore, the purpose of this study is to estimate the progression rates to impair glucose regulation and diabetes in the Korean population-based Korea national Diabetes program.

Conditions
-----------------
Impaired Glucose Tolerance, Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: fastic serum glucose >100 and/or pp2 serum glucose <200 Exclusion Criteria: known diabetes organ failure(For example, liver, kidney) known malignancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| life style modification<br>everyone in this study was advised about their life style, diet, exercise habits. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fasting serum glucose, fasting plasma insulin,post prandial serum glucose, post prandial plasma insulin, hbA1c |  | 0.1.3.5 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NGT, IGT, diabetes